Squarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second q

Corient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in th

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to

Concurrent Investment Advisors LLC bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the

On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick am

UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target

GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likel

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a lea

Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the

Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT)

Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, acco

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and ri

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth fa

The health care sector's oversold stocks present buying opportunities for undervalued companies.

Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy

Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.7% during

Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth

Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evide

Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and low

Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and l

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lower

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the

U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Est

Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $582.000 million-$592.000 million to $590.00

Grew total revenue to  $150.3 million and testing revenue to $145.7 million , representing increases

Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and

Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overwe

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raise

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price t

On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ

On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, In

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $570.000 million-$582.000 million to $582.00

Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.52 per share which beat the analyst consens

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the

Jefferies analyst Tycho Peterson initiates coverage on Veracyte (NASDAQ:VCYT) with a Buy rating a

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price t

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lower